Moleculin Biotech (MBRX) Property, Plant & Equipment (Net) Growth (3y) (2019 - 2026)
Moleculin Biotech (MBRX) Property, Plant & Equipment (Net) Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.05% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.65% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 411.50% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -3.34% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 16.78% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.66% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 109.44% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 19.96% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -35.31% |
| Dec 31, 2025 | -34.30% |
| Sep 30, 2025 | -36.87% |
| Jun 30, 2025 | -33.65% |
| Mar 31, 2025 | -25.89% |
| Dec 31, 2024 | -22.23% |
| Sep 30, 2024 | -18.66% |
| Jun 30, 2024 | -17.60% |
| Mar 31, 2024 | -18.17% |
| Dec 31, 2023 | -17.42% |
| Sep 30, 2023 | -24.46% |
| Jun 30, 2023 | -1.28% |
| Mar 31, 2023 | -3.44% |
| Dec 31, 2022 | -4.53% |
| Sep 30, 2022 | -5.10% |
| Jun 30, 2022 | -5.44% |
| Mar 31, 2022 | -10.21% |
| Dec 31, 2021 | -9.96% |
| Sep 30, 2021 | -3.35% |
| Jun 30, 2021 | 147.67% |